Hernandez AF, Green JB, Janmohamed S, DAgostino RB, Sr., Granger CB, Jones NP, Leiter LA, Rosenberg AE, Sigmon KN, Somerville MC, Thorpe KM, McMurray JJV, Del Prato S
GLP-1-based therapies and resmetirom operate through distinct and potentially complementary mechanisms: while resmetirom exerts direct hepatic effects by activating THR- to enhance mitochondrial function, reduce hepatic lipogenesis, and promote lipid oxidation specifically in hepatocytes, GLP-1 RAs and multi-agonists address the upstream metabolic drivers of MASLD including insulin resistance, obesity, and systemic inflammation
Avoid repeated freeze-thaw cycles of reconstituted solution, and never leave vials at room temperature longer than necessary
A., Miners, J